115 related articles for article (PubMed ID: 20410637)
1. Sulphonamides as inhibitors of protein tyrosine phosphatase 1B: a three-dimensional quantitative structure-activity relationship study using self-organizing molecular field analysis approach.
Thareja S; Kokil GR; Aggarwal S; Bhardwaj TR; Kumar M
Chem Pharm Bull (Tokyo); 2010 Apr; 58(4):526-32. PubMed ID: 20410637
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR studies on a series of 2,4-thiazolidinedione derivatives: a self- organizing molecular field analysis approach to design novel PTP 1B inhibitors.
Malla P; Kumar M
Med Chem; 2013 Sep; 9(6):828-45. PubMed ID: 22974292
[TBL] [Abstract][Full Text] [Related]
3. Cheminformatics based 3D-QSAR study on a series of 1,2-naphthoquinone derivatives as PTP 1B inhibitors.
Pahwa P; Papreja M
Acta Pol Pharm; 2012; 69(3):535-43. PubMed ID: 22594268
[TBL] [Abstract][Full Text] [Related]
4. Self-organizing molecular field analysis of 2,4-thiazolidinediones: A 3D-QSAR model for the development of human PTP1B inhibitors.
Thareja S; Aggarwal S; Bhardwaj TR; Kumar M
Eur J Med Chem; 2010 Jun; 45(6):2537-46. PubMed ID: 20236737
[TBL] [Abstract][Full Text] [Related]
5. Quantitative structure-activity relationship (QSAR) and design of novel ligands that demonstrate high potency and target selectivity as protein tyrosine phosphatase 1B (PTP 1B) inhibitors as an effective strategy used to model anti-diabetic agents.
Arthur DE; Ejeh S; Uzairu A
J Recept Signal Transduct Res; 2020 Dec; 40(6):501-520. PubMed ID: 32397858
[TBL] [Abstract][Full Text] [Related]
6. Protein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus.
Thareja S; Aggarwal S; Bhardwaj TR; Kumar M
Med Res Rev; 2012 May; 32(3):459-517. PubMed ID: 20814956
[TBL] [Abstract][Full Text] [Related]
7. Validation of formylchromane derivatives as protein tyrosine phosphatase 1B inhibitors by pharmacophore modeling, atom-based 3D-QSAR and docking studies.
Malla P; Kumar R; Kumar M
Chem Biol Drug Des; 2013 Jul; 82(1):71-80. PubMed ID: 23506477
[TBL] [Abstract][Full Text] [Related]
8. Protein tyrosine phosphatase 1B inhibitors as antidiabetic agents - A brief review.
Verma M; Gupta SJ; Chaudhary A; Garg VK
Bioorg Chem; 2017 Feb; 70():267-283. PubMed ID: 28043717
[TBL] [Abstract][Full Text] [Related]
9. Novel Imbricatolic acid derivatives as protein tyrosine phosphatase-1B inhibitors: Design, synthesis, biological evaluation and molecular docking.
Khan MF; Azad CS; Kumar A; Saini M; Narula AK; Jain S
Bioorg Med Chem Lett; 2016 Apr; 26(8):1988-92. PubMed ID: 26965864
[TBL] [Abstract][Full Text] [Related]
10. 2,4-Thiazolidinediones as PTP 1B Inhibitors: A Mini Review (2012-2018).
Verma SK; Yadav YS; Thareja S
Mini Rev Med Chem; 2019; 19(7):591-598. PubMed ID: 30968766
[TBL] [Abstract][Full Text] [Related]
11. Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control.
Popov D
Biochem Biophys Res Commun; 2011 Jul; 410(3):377-81. PubMed ID: 21683066
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, structure-activity relationship and docking studies of substituted aryl thiazolyl phenylsulfonamides as potential protein tyrosine phosphatase 1B inhibitors.
Varshney K; Gupta S; Rahuja N; Rawat AK; Singh N; Tamarkar AK; Srivastava AK; Saxena AK
ChemMedChem; 2012 Jul; 7(7):1185-90. PubMed ID: 22615198
[No Abstract] [Full Text] [Related]
13. Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors.
Forghieri M; Laggner C; Paoli P; Langer T; Manao G; Camici G; Bondioli L; Prati F; Costantino L
Bioorg Med Chem; 2009 Apr; 17(7):2658-72. PubMed ID: 19297174
[TBL] [Abstract][Full Text] [Related]
14. Human protein tyrosine phosphatase 1B inhibitors: QSAR by genetic function approximation.
Sachan N; Kadam SS; Kulkarni VM
J Enzyme Inhib Med Chem; 2007 Jun; 22(3):267-76, 371-3. PubMed ID: 17674807
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and 3D-QSAR studies of imidazolidine-2,4-dione derivatives as novel protein tyrosine phosphatase 1B inhibitors.
Wang MY; Jin YY; Wei HY; Zhang LS; Sun SX; Chen XB; Dong WL; Xu WR; Cheng XC; Wang RL
Eur J Med Chem; 2015 Oct; 103():91-104. PubMed ID: 26342135
[TBL] [Abstract][Full Text] [Related]
16. Protein-Tyrosine Phosphatase-1B Mediates Sleep Fragmentation-Induced Insulin Resistance and Visceral Adipose Tissue Inflammation in Mice.
Gozal D; Khalyfa A; Qiao Z; Akbarpour M; Maccari R; Ottanà R
Sleep; 2017 Sep; 40(9):. PubMed ID: 28651353
[TBL] [Abstract][Full Text] [Related]
17. Rational design of selective organoruthenium inhibitors of protein tyrosine phosphatase 1B.
Ong JX; Yap CW; Ang WH
Inorg Chem; 2012 Nov; 51(22):12483-92. PubMed ID: 23121648
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of thiazolidine-2,4-dione/benzazole derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B): Antihyperglycemic activity with molecular docking study.
Hidalgo-Figueroa S; Estrada-Soto S; Ramírez-Espinosa JJ; Paoli P; Lori G; León-Rivera I; Navarrete-Vázquez G
Biomed Pharmacother; 2018 Nov; 107():1302-1310. PubMed ID: 30257345
[TBL] [Abstract][Full Text] [Related]
19. Docking simulations and in vitro assay unveil potent inhibitory action of papaverine against protein tyrosine phosphatase 1B.
Bustanji Y; Taha MO; Al-Masri IM; Mohammad MK
Biol Pharm Bull; 2009 Apr; 32(4):640-5. PubMed ID: 19336898
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes.
Qian S; Zhang M; He Y; Wang W; Liu S
Future Med Chem; 2016 Jul; 8(11):1239-58. PubMed ID: 27357615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
